Drug Profile
MK 5108
Alternative Names: MK-5108; VX-689Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Merck & Co
- Class Antineoplastics
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO)
- 23 Mar 2011 Phase-I development is ongoing in USA (NCT00543387)
- 08 Jun 2010 Adverse events, efficacy and pharmacokinetics data from a phase I trial in late-stage and/or refractory solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)